SCHEMBL15020705

SCHEMBL15020705

COc1cccc(-c2cc(N3CCCC3CO)nc3c(-c4ccc(C)c(F)c4)c(C)nn23)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.45
TDP1 Q9NUW8 1/20 0.41
MAPK1 P28482 2/20 0.40
CRHR1 P34998 1/20 0.40
CDK1 P06493 1/20 0.38
FPR2 P25090 1/20 0.37
SCN9A Q15858 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ITGB2 P05107 1/20 0.37
ICAM1 P05362 1/20 0.37
ITGAL P20701 1/20 0.37
THRB P10828 1/20 0.36
SRC P12931 2/20 0.35
CHRM3 P20309 1/20 0.35
TP53 P04637 1/20 0.35
GNRHR P30968 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020750 0.90 MAPT (0.46) MAPTTDP1MAPK1CRHR1CDK1
SCHEMBL257538 0.90 MAPT (0.46) MAPTTDP1MAPK1CRHR1CDK1
SCHEMBL15021467 0.88 MAPT (0.48) MAPTTDP1MAPK1CRHR1FPR2
SCHEMBL15020733 0.88 MAPT (0.45) MAPTTDP1MAPK1CRHR1CDK1
SCHEMBL15020759 0.88 MAPT (0.45) MAPTTDP1MAPK1CRHR1CDK1
SCHEMBL15020596 0.88 MEN1 (0.43) MAPK1CDK1FPR2SCN9AALDH1A1
SCHEMBL15020826 0.87 FPR2 (0.43) MAPTMAPK1FPR2SCN9AKDM4E
SCHEMBL15020620 0.87 MAPT (0.44) MAPTTDP1MAPK1CRHR1CDK1
SCHEMBL15021446 0.86 MAPT (0.45) MAPTMAPK1CRHR1FPR2SCN9A
SCHEMBL257511 0.86 MAPT (0.45) MAPTMAPK1CRHR1FPR2SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US claimed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP claimed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US claimed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 MAPT 2617/4885TDP1 3897/4885MAPK1 519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.